Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Stock Surged Today

By Joe Tenebruso - Aug 7, 2020 at 2:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker hopes its experimental new therapy could change the lives of people who struggle with Alzheimer’s disease.

What happened

Shares of Biogen (BIIB 1.27%) rose sharply on Friday after the biotech company said its experimental Alzheimer's disease drug had been granted priority review status by the U.S. Food and Drug Administration (FDA). As of 3:25 p.m. EDT, Biogen's stock was up more than 10%.

So what

The priority review designation will accelerate the FDA's timeline. The regulatory agency is now expected to make its approval decision by March 7, 2021. If approved, aducanumab, as the drug is called, would be the first therapy to meaningfully alter the course of Alzheimer's disease.

"If aducanumab is determined to be effective in reducing the decline in cognition and activities of daily living resulting from progression of this disease by addressing the underlying disease pathology, it will deliver meaningful benefits to those who most need them," said Dr. Christopher van Dyck, director of the Yale Alzheimer's Disease Research Center, in a press release.

People at working in a laboratory

Investors are excited about the potential of Biogen's Alzheimer's disease treatment. Image source: Getty Images.

Biogen licensed aducanumab from Switzerland-based biotech company Neurimmune back in 2007. In October 2017, Biogen partnered with Japanese pharmaceutical company Eisai to develop and commercialize the drug.

Now what

Biogen's decision to move forward with aducanumab at this time is somewhat surprising. In March 2019, the biotech giant halted studies of the drug after an analysis showed it was unlikely to meet the primary endpoints of clinical trials. 

However, Biogen CEO Michel Vounatsos seems undeterred. "We believe that aducanumab marks the beginning of a new era of potential treatments for Alzheimer's disease that will inspire even more discovery and innovation to bring hope to those affected by this devastating disease," he said.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$220.99 (1.27%) $2.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.